ICS 2018: Safety and Efficacy of Desmopressin an Orally Disintegrating Tablet 25/50Μg for Patients with Nocturia and Mild Daytime Urinary Symptoms

Philadelphia, PA (UroToday.com) Dr. Weis and his group were aimed to analyses efficacy and safety data from two phase 3 trials of desmopressin ODT therapy in a subgroup of patients with nocturia and NP as well as mild daytime voiding dysfunction. Desmopressin as known is orally disintegrating tablet (ODT) 25/50µg is to date approved in over 30 countries for symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.

They derived their data from two 3-month, phase 3 double-blind randomized placebo-controlled trials of desmopressin ODT in males (50/75µg; NCT01262456) and females (25µg; NCT01223937) with ≥2 voids per night during 3-day screening. Mild daytime LUTS associated with OAB/BPO were not specifically excluded, but concomitant medications for OAB/BPO (antimuscarinics, 5 alpha-reductase inhibitors, alpha-blockers) had to be stable for 3 months prior to screening. Medical history was used to exclude severe daytime voiding dysfunction (urge urinary incontinence >1 episode/day; urgency >1 episode/day; frequency >8 daytime voids/day). Patients with severe BPO (urinary retention or post-void residual volume >250mL; surgical treatment within the past 6 months; suspicion of bladder outlet obstruction or urine flow <5 mL/s) were also excluded. Nocturnal polyuria index (NPI) was recorded at baseline, with NPI>33% indicating NP. In this post-hoc analysis, only patients who enrolled with NP were included. Based on medical history or concomitant medication, patients were grouped into those with daytime symptoms, or without daytime symptoms (referred to as “pure NP”). For males, only those randomized to placebo or 50µg (not 75µg) desmopressin are included in this analysis. Baseline characteristics, nocturnal voids and safety parameters were investigated.

There was 196 women with “pure NP”, 35 women with NP and OAB, 152 men with “pure NP” and 75 men with NP and OAB and/or BPO. Baseline voiding characteristics for patients with and without OAB and/or BPO were similar (Table 1).

Table 1

Desmopressin ODT demonstrated similar efficacy in patients with pure NP and those with NP and OAB+/BPO in terms of reduction in nocturnal voids relative to placebo and percentage of patients achieving 33% reduction in nocturnal voids (Table 2).

Table 2

All groups showed greater improvement with desmopressin compared with placebo. Difference vs placebo in those with OAB+/BPO did not reach statistical significance due to small sample sizes.

Mild daytime urinary symptoms did not impact treatment comparison (judged by p value of treatment by symptom subgroup factor). The non-significant p-value of the treatment effect reflects the smaller sample size in those with mild daytime symptoms.

No worsening of daytime urinary disorders was noted from the recorded treatment-emergent adverse events. No significant increase in daytime voids was seen in any group except men with OAB+/BPO receiving desmopressin, who experienced 0.59 additional daytime voids per day. When patients with OAB/BPO were treated with the recommended gender-specific doses (25µg for women and 50µg for men), the incidence of severe (≤125mmol/L) and clinically significant (126–129mmol/L) hyponatraemia was low (Table 3), and all cases would have been captured by serum sodium monitoring.

Table 3

What they found that desmopressin demonstrates a similar safety and efficacy profile in nocturia patients with NP and mild daytime voiding dysfunction (OAB+/BPO) as in patients with pure NP. A small, clinically non-significant increase in daytime voids was observed in men with OAB+/BPO.

At the end they conclude that nocturia patients with NP and mild daytime voiding dysfunction (OAB or BPO) were included in the phase III trials of desmopressin ODT for nocturia. Reduction in nocturnal voids in this subgroup was consistent with the reduction in voids for those with pure NP without daytime voiding dysfunction. No additional safety concerns were identified.

Authors: Weiss J P1, Malmberg A2, Juul K V2

Written by: Bilal Farhan, MD; Clinical Instructor, Female Pelvic Medicine and Reconstructive Surgery, University of California, Irvine Medical Center, Twitter: @Bilalfarhan79 at the 2018 ICS International Continence Society Meeting - August 28 - 31, 2018 – Philadelphia, PA USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe